Switch theme
Sign up to access all valuation multiples
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
2006
48
LTM Revenue $0.5M
LTM EBITDA -$21.9M
$129M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sequana Medical has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of -$21.9M.
In the most recent fiscal year, Sequana Medical achieved revenue of $0.1M and an EBITDA of -$48.4M.
Sequana Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sequana Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.4M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$21.9M | XXX | -$48.4M | XXX | XXX | XXX |
| EBITDA Margin | -4725% | XXX | -38978% | XXX | XXX | XXX |
| EBIT | -$21.5M | XXX | -$21.5M | XXX | XXX | XXX |
| EBIT Margin | -4624% | XXX | -17273% | XXX | XXX | XXX |
| Net Profit | -$28.7M | XXX | -$52.6M | XXX | XXX | XXX |
| Net Margin | -6192% | XXX | -42326% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $42.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Sequana Medical's stock price is EUR 1 (or $2).
Sequana Medical has current market cap of EUR 72.9M (or $85.9M), and EV of EUR 109M (or $129M).
See Sequana Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $129M | $85.9M | XXX | XXX | XXX | XXX | $-0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Sequana Medical has market cap of $85.9M and EV of $129M.
Sequana Medical's trades at 1035.3x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Sequana Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sequana Medical has a P/E ratio of -3.0x.
See valuation multiples for Sequana Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85.9M | XXX | $85.9M | XXX | XXX | XXX |
| EV (current) | $129M | XXX | $129M | XXX | XXX | XXX |
| EV/Revenue | 277.1x | XXX | 1035.3x | XXX | XXX | XXX |
| EV/EBITDA | -5.9x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -6.0x | XXX | -6.0x | XXX | XXX | XXX |
| EV/Gross Profit | 296.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSequana Medical's last 12 month revenue growth is 782%
Sequana Medical's revenue per employee in the last FY averaged $3K, while opex per employee averaged $0.4M for the same period.
Sequana Medical's rule of 40 is -3353% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sequana Medical's rule of X is -2771% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sequana Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 782% | XXX | 648% | XXX | XXX | XXX |
| EBITDA Margin | -4725% | XXX | -38978% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3353% | XXX | -38197% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2771% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1003% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17348% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sequana Medical acquired XXX companies to date.
Last acquisition by Sequana Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Sequana Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sequana Medical founded? | Sequana Medical was founded in 2006. |
| Where is Sequana Medical headquartered? | Sequana Medical is headquartered in Belgium. |
| How many employees does Sequana Medical have? | As of today, Sequana Medical has 48 employees. |
| Who is the CEO of Sequana Medical? | Sequana Medical's CEO is Mr. Ian Crosbie. |
| Is Sequana Medical publicy listed? | Yes, Sequana Medical is a public company listed on BRU. |
| What is the stock symbol of Sequana Medical? | Sequana Medical trades under SEQUA ticker. |
| When did Sequana Medical go public? | Sequana Medical went public in 2019. |
| Who are competitors of Sequana Medical? | Similar companies to Sequana Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sequana Medical? | Sequana Medical's current market cap is $85.9M |
| What is the current revenue of Sequana Medical? | Sequana Medical's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Sequana Medical? | Sequana Medical revenue growth (NTM/LTM) is 782%. |
| What is the current EV/Revenue multiple of Sequana Medical? | Current revenue multiple of Sequana Medical is 277.1x. |
| Is Sequana Medical profitable? | Yes, Sequana Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sequana Medical? | Sequana Medical's last 12 months EBITDA is -$21.9M. |
| What is Sequana Medical's EBITDA margin? | Sequana Medical's last 12 months EBITDA margin is -4725%. |
| What is the current EV/EBITDA multiple of Sequana Medical? | Current EBITDA multiple of Sequana Medical is -5.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
